SCHEMBL6315475

SCHEMBL6315475

NC(=O)c1c(-c2ccsc2)noc1NC(=O)c1ccco1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 1/20 0.50
FLT1 P17948 1/20 0.50
KDR P35968 1/20 0.50
IKBKE Q14164 1/20 0.47
TBK1 Q9UHD2 1/20 0.47
ALDH1A1 P00352 5/20 0.46
MAPT P10636 5/20 0.46
KMT2A Q03164 5/20 0.46
MAPK10 P53779 1/20 0.46
NPC1 O15118 6/20 0.45
RAB9A P51151 6/20 0.45
HPGD P15428 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
FLT3 P36888 1/20 0.45
MEN1 O00255 4/20 0.42
KDM4E B2RXH2 1/20 0.41
CACNA1B Q00975 1/20 0.41
APBA1 Q02410 1/20 0.41
PTPN2 P17706 1/20 0.41
PTPN1 P18031 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6319874 0.90 KIT (0.51) KITFLT1KDRALDH1A1MAPT
SCHEMBL6316874 0.85 IKBKE (0.57) IKBKETBK1ALDH1A1MAPTKMT2A
Butyramide SCHEMBL28753403 0.84 KIT (0.45) KITFLT1KDRIKBKETBK1
SCHEMBL27591737 0.84 KIT (0.49) KITFLT1KDRIKBKETBK1
SCHEMBL6316187 0.83 KIT (0.46) KITFLT1KDRIKBKETBK1
SCHEMBL6319331 0.82 HDAC3 (0.47) KITFLT1KDRALDH1A1KMT2A
SCHEMBL6315901 0.82 MAPT (0.54) IKBKETBK1ALDH1A1MAPTKMT2A
SCHEMBL6316823 0.80 POLB (0.54) IKBKETBK1ALDH1A1MAPTKMT2A
SCHEMBL6322761 0.79 FLT3 (0.45) ALDH1A1MAPTKMT2ANPC1RAB9A
SCHEMBL6314886 0.79 MAPT (0.50) IKBKETBK1ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 KIT 4264/4885FLT1 3886/4885KDR 3191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.